Monoamine oxidases and related amine oxidases as phase I enzymes in the metabolism of xenobiotics

  • M. Strolin Benedetti
  • K. F. Tipton
Part of the Journal of Neural Transmission. Supplement book series (NEURAL SUPPL, volume 52)


To date most of the interest in oxidative metabolism of xenobiotics has been devoted to the role of the microsomal cytochrome P-450 system and to establish the basis for classifying and naming P450 enzymes. The contribution of amine oxidases to the metabolism of xenobiotics has been largely neglected, with the exception of the contribution of monoamine oxidases (MAOs) to the metabolism of exogenous tyramine and the studies of the “cheese effect” produced as the result of ingestion of large amounts of tyramine-containing foods under particular conditions. A review of the involvement of the mitochondrial MAOs in drug metabolism was published in 1988. Since that time, considerable additional evidence has appeared in the literature to support the contribution of MAOs to drug metabolism. In addition, the involvement of other amine oxidases in the metabolism of foreign compounds has been established. A second review on the contribution of amine oxidases to the metabolism of xenobiotics was therefore published in 1994. On an arbitrary basis, the heterogeneous class of amine oxidases can be divided into two types according to their prosthetic group: the flavineadenine dinucleotide (FAD)-dependent amine oxidases (Monoamine Oxidase and Polyamine Oxidase) and the amine oxidases not containing FAD (Semicarbazide-sensitive amine oxidases). In this overview, the contributions of these two types in xenobiotic metabolism are considered separately.


Monoamine Oxidase Amine Oxidase Oxidative Deamination Polyamine Oxidase Human Umbilical Artery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Beedham C (1985) Molybdenum hydroxylases as drug-metabolizing enzymes. Drug Metab Rev 16: 119–156PubMedCrossRefGoogle Scholar
  2. Beresdorf AP, Macrae PV, Stopher DA (1988a) Metabolism of amlodipine in the rat and the dog: a species difference. Xenobiotica 18: 169–182CrossRefGoogle Scholar
  3. Beresdorf AP, McGibney D, Humphrey MJ, Macrae PV, Stopher DA (1988b) Metabolism and kinetics of amlodipine in man. Xenobiotica 18: 245–254CrossRefGoogle Scholar
  4. Bey P, Bolkenius FN, Seiler N, Casara P (1985) N-2,3-butadienyl-1,4-butanediamine derivatives: potent irreversible inactivators of mammalian polyamine oxidase. J Med Chem 28: 1–2PubMedCrossRefGoogle Scholar
  5. Bitonti AJ, Dumont JA, Bush TL, Stemerick DM, Edwards ML, McCann PP (1990) Bis(benzyl)polyamine analogs as novel substrates for polyamine oxidase. J Biol Chem 265: 382–388PubMedGoogle Scholar
  6. Callingham BA, Holt A, Elliot J (1990) Some aspects of the pharmacology of semicarbazide-sensitive amine oxidases. J Neural Transm [Suppl] 32: 279–290Google Scholar
  7. Cao Danh H, Strolin Benedetti M, Dostert P (1984) In: Tipton KF, Dostert P, Strolin Benedetti M (ed) Monoamine oxidase and disease: prospects for therapy with reversible inhibitors. Academic Press, London, p 301Google Scholar
  8. Cesura AM, Imhof R, Galva MD, Kettler R, Da Prada M (1988) Interactions of the novel inhibitors of MAO-B Ro 19-6327 and Ro 16-6491 with the active site of the enzyme. Pharmacol Res Commun 20[Suppl IV]: 51–61PubMedCrossRefGoogle Scholar
  9. Clark AM, Baker JK, McChesney JD (1984) Excretion, distribution, and metabolism of primaquine in rats. J Pharm Sci 73: 502–506PubMedCrossRefGoogle Scholar
  10. Coomes MW, Prough RA (1983) The mitochondrial metabolism of 1,2-disubstituted hydrazines, procarbazine and 1,2-dimethylhydrazine. Drug Metab Dispos 11(6): 550–555PubMedGoogle Scholar
  11. Delia Corte L, Callingham BA (1977) The influence of age and adrenalectomy on rat heart monoamine oxidase. Biochem Pharmacol 26: 407–415PubMedCrossRefGoogle Scholar
  12. Dixon CM, Parkt GR, Parbit MH (1994) Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver. Biochem Pharmacol 42: 1253–1257CrossRefGoogle Scholar
  13. Dostert P, Strolin Benedetti M (1988) Les bases de la neurotoxicité du MPTP. L’Encéphale 14: 399–412PubMedGoogle Scholar
  14. Dostert P, Strolin Benedetti M, Tipton KF (1989) Interaction of monoamine oxidase with substrates and inhibitors. Med Res Rev 9: 45–89PubMedCrossRefGoogle Scholar
  15. Duine JA (1991) Quinoproteins: enzymes containing the quinonoid cofactor pyrroloquinoline quinone, topaquinone or tryptophan-tryptophan quinone. Eur J Biochem 200: 271–284PubMedCrossRefGoogle Scholar
  16. Edwards G, McGrath CS, Ward SA, Suparanond W, Pukrittayakamee S, Davis TME, White NJ (1993) Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. Br J Clin Pharmacol 35: 193–198PubMedCrossRefGoogle Scholar
  17. Fang J, Gorrod JW (1991) Dehydration is the first step in the bioactivation of haloperidol to its pyridinium metabolite. Toxicol Lett 59: 117–123PubMedCrossRefGoogle Scholar
  18. Fang J, Rosen A, Gorrod JW (1993) Investigation of heterocyclic amines as potential substrates and inhibitors of monoamine oxidase. Pharm Sci Comm 4: 75–79Google Scholar
  19. Ferkany JW, Andree TH, Clarke DE, Enna SJ (1981) Neurochemical effects of kojic amine, a gabamimetic, and its interaction with benzylamine oxidase. Neuropharmacology 20: 1177–1182PubMedCrossRefGoogle Scholar
  20. Fitton A, Benfield P (1990) Dopexamine hydrochloride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute cardiac insufficiency. Drugs 39(2): 308–330PubMedCrossRefGoogle Scholar
  21. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R, Alexoff D, Shea C, Schlyer D, Wolf AP, Warner D, Zezulkova I, Cilento R (1996) Inhibition of monoamine oxidase B in the brains of smokers. Nature 379: 733–736PubMedCrossRefGoogle Scholar
  22. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJ, Baber NS (1991) The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 31: 291–294PubMedCrossRefGoogle Scholar
  23. Freestone S, Li Kam Wa TC, Lee MR (1992) The effect of the monoamine oxidase-B inhibitor selegiline on the metabolism of y-L-glutamyl-L-dopa (gludopa) in man. Proceedings of the BPS, September 9–11, 1992, p 74Google Scholar
  24. Garland WA, Miwa BJ, Dairman W, Kappell B, Chiueh MC, Divoll M, Greenblatt DJ (1983) Identification of 7-chloro-5-(2’-fluorophenyl)-2,3-dihydro-2-oxo-1H-1, 4-benzodiazepine-1-acetaldehyde, a new metabolite of flurazepam in man. Drug Metab Dispos 11: 70–72PubMedGoogle Scholar
  25. Guengerich FP (1995) Influence of nutrients and other dietary materials on cytochrome P-450 enzymes. Am J Clin Nutr 61 [Suppl]: 651S–658SPubMedGoogle Scholar
  26. Halliwell B (1989) Oxidants and the central nervous system: some fundamental questions. Acta Neurol Scand 126: 23–33CrossRefGoogle Scholar
  27. Holt A, Callingham BA (1994) The ex vivo effects of procarbazine and methylhydrazine on some rat amine oxidase activities. J Neural Transm 41: 439–443Google Scholar
  28. Janssen de Varebeke P, Cavalier R, David-Remacle M, Youdim MBH (1988) Formation of the neurotransmitter glycine from the anticonvulsant milacemide is mediated by brain monoamine oxidase B. J Neurochem 50: 1011–1016CrossRefGoogle Scholar
  29. Jeong TC, Yang KH, Holsapple MP (1994) Recovery of dimethylnitrosamine-induced immunosuppression by pargyline in the mixed cultures of murine hepatocytes and splenocytes. Life Sci 54(9): 605–613PubMedCrossRefGoogle Scholar
  30. Kenny P, Tipton KF, Strolin Benedetti M (1996) 6th Amine Rappaport Symposium and 7th International Amine Oxidase Workshop, Haifa, June 10–13, 1996. Book of Abstracts, p 40Google Scholar
  31. Kinemuchi H, Fowler CJ, Tipton KF (1987) The neurotoxicity of l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its relevance to Parkinson’s disease. Neurochem Int 11: 359–373PubMedCrossRefGoogle Scholar
  32. Kopin IJ (1993) Monoamine oxidase (MAO): relationships to foods, poisons and medicines. Biogen Amines 9: 355–365Google Scholar
  33. Lake BG, Phillips JC, Cottrell RC, Gangolli SD (1978) Biological oxidation of nitrogen. Elsevier/North Holland, New York, p 131Google Scholar
  34. Lee PC, Werlin SL (1995) The induction of hepatic cytochrome P450 3A in rats: effects of age. P.S.E.B.M. 210: 134–139Google Scholar
  35. Lewinsohn R (1984) Mammalian monoamine-oxidizing enzymes, with special reference to benzylamine oxidase in human tissues. Braz J Med Biol Res 17: 223–256PubMedGoogle Scholar
  36. Liczano JM, Fernández de Arriba A, Lyles GA, Unzeta M (1994) Several aspects of the amine oxidation by semicarbazide-sensitive amine oxidase (SSAO) from bovine lung. J Neural Transm [Suppl] 41: 415–420Google Scholar
  37. Lyles GA (1994) Properties of mammalian tissue-bound semicarbazide-sensitive amine oxidase: possible clues to its physiological function? J Neural Transm [Suppl] 41: 387–396Google Scholar
  38. Lyles GA, Chalmers J (1992) The metabolism of aminoacetone to methylglyoxal by semicarbazide-sensitive amine oxidase in human umbilical artery. Biochem Pharmacol 43: 1409–1414PubMedCrossRefGoogle Scholar
  39. Lyles GA, Marshall CM, McDonald IA, Bey P, Palfreyman MG (1987) Inhibition of rat aorta semicarbazide-sensitive amine oxidase by 2-phenyl-3-haloallylamines and related compounds. Biochem Pharmacol 36: 2847–2853PubMedCrossRefGoogle Scholar
  40. Mageed AA, Williams D, Faray B, Messina C, Ragab AH (1993) The effect of prednisone therapy on platelet monoamine oxidase and plasma catecholamine levels in children with acute lymphocytic leukemia. Cancer Res Ther Control 3: 79–85Google Scholar
  41. Maret G, Testa B, Jenner P, el Tayar N, Carrupt PA (1990) The MPTP story: MAO activates tetrahydropyridine derivatives to toxins causing parkinsonism. Drug Metab Rev 22: 291–332PubMedCrossRefGoogle Scholar
  42. Markey SP, Schmuff NR (1986) The pharmacology of the parkinsonian syndrome producing neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and structurally related compounds. Med Res Rev 6: 389–429PubMedCrossRefGoogle Scholar
  43. McEwen CM, Harrison DC (1965) Abnormalities of serum monoamine oxidase in chronic congestive heart failure. J Lab Clin Med 65(4): 546–559PubMedGoogle Scholar
  44. McEwen CM Jr, Castell DO (1967) Abnormalities of serum monoamine oxidase in chronic liver disease. J Lab Clin Med 70: 36–47PubMedGoogle Scholar
  45. McIntire WS (1992) Wither PQQ. Essays Biochem 27: 119–134PubMedGoogle Scholar
  46. Mihaly GW, Ward SA, Edwards G, L’E Orme M, Breckenridge AM (1984) Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. Br J Clin Pharmacol 17: 441–446PubMedCrossRefGoogle Scholar
  47. Murata K, Noda K, Kohno K, Samejima M (1988) Bioavailability and pharmacokinetics of oral dopamine in dogs. J Pharm Sci 77(7): 565–568PubMedCrossRefGoogle Scholar
  48. Murphy PJ, Williams TL, Kau DLK (1976) Disposition of dobutamine in the dog. J Pharmacol Exp Ther 199(2): 423–431PubMedGoogle Scholar
  49. Nelson TJ, Boor PJ (1982) Allylamine cardiotoxicity-IV metabolism to acrolein by cardiovascular tissues. Biochem Pharmacol 31: 509–514PubMedCrossRefGoogle Scholar
  50. Ni Y, Xu Y, Wang M (1992) In: Proceedings of the Fourth North American ISSX Meeting, Bal Harbour, FL, November 2–6, 1992, p 70Google Scholar
  51. Nilsson SE, Tryding N, Tufvesson G (1968) Serum monoamine oxidase (MAO) in diabetes mellitus and some other internal diseases. Acta Med Scand 184: 105–108PubMedCrossRefGoogle Scholar
  52. Nishiyama S, Yoshikawa M, Yamaguchi I (1992) An orally effective peripheral dopamine prodrug: docarpamine (TA-870). Cardiovasc Drug Rev 10: 101–116CrossRefGoogle Scholar
  53. O’Brien EM, Tipton KF, Strolin Benedetti M, Bonsignori A, Marrari P, Dostert P (1991) Is the oxidation of milacemide by monoamine oxidase a major factor in its anticonvulsant actions? Biochem Pharmacol 41: 1731–1737PubMedCrossRefGoogle Scholar
  54. O’Brien EM, Dostert P, Pevarello P, Tipton KF (1994) Interactions of some analogues of the anticonvulsant milacemide with monoamine oxidase. Biochem Pharmacol 48: 905–914PubMedCrossRefGoogle Scholar
  55. O’Brien EM, Dostert P, Tipton KF (1995) Species differences in the interactions of the anticonvulsant milacemide and some analogues with monoamine oxidase-B. Biochem Pharmacol 50: 317–324PubMedCrossRefGoogle Scholar
  56. Phillips JC, Bex C, Lake BG, Cottrell RC, Gangolli SD (1982) Inhibition of dimethylni-trosamine metabolism by some heterocyclic compounds and by substrates and inhibitors of monoamine oxidase in the rat. Cancer Res 42: 3761–3765PubMedGoogle Scholar
  57. Precious E, Gunn CE, Lyles G A (1988) Deamination of methylamine by semicarbazide-sensitive amine oxidase in human umbilical artery and rat aorta. Biochem Pharmacol 37: 707–713PubMedCrossRefGoogle Scholar
  58. Roberts BJ, Shoaf SE, Jeong KS, Song BJ (1994) Induction of CYP2E1 in liver, kidney, brain and intestine during chronic ethanol administration and withdrawal: evidence that CYP2E1 possesses a rapid phase half-life of 6 hours or less. Biochem Biophys Res Commun 205: 1064–1071PubMedCrossRefGoogle Scholar
  59. Saura J, Kettler R, Da Prada M, Richards JG (1992) Quantitative enzyme radioautogra-phy with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J Neurosci 12: 1977–1999PubMedGoogle Scholar
  60. Saura J, Nadal E, van den Berg B, Vila’ M, Richards JG, Bombi JA, Mahy N (1994) Localization of monoamine oxidases in human peripheral tissues. 6th Amine Oxidase Workshop and 5th Trace Amine Conference, Saskatoon, 31 July-3 August 1994. Book of Abstracts No A 03Google Scholar
  61. Saura J, Richards JG, Mahy N (1994) Differential age-related changes of MAO-A and MAO-B in mouse brain and peripheral organs. Neurobiol Aging 15: 399–408PubMedCrossRefGoogle Scholar
  62. Scaman CH, Palcic MM (1992) Stereochemical course of tyramine oxidation by semicarbazide-sensitive amine oxidase. Biochemistry 31: 6829–6841PubMedCrossRefGoogle Scholar
  63. Schwartz MA, Postma E (1970) Metabolism of flurazepam, a benzodiazepine, in man and dog. J Pharm Sci 59: 1800–1806PubMedCrossRefGoogle Scholar
  64. Seiler N (1987) In: McCann PP, Pegg AE, Sjoerdsma A (eds) Inhibition of polyamine metabolism. Academic Press, London, p 49Google Scholar
  65. Seiler N, Bolkenius FN, Knodgen B, Mamont P (1980) Polyamine oxidase in rat tissues. Biochim Biophys Acta 615: 480–488PubMedCrossRefGoogle Scholar
  66. Shah NS, Himwich HE (1971) Study with mescaline-8-C14 in mice: effect of amine oxidase inhibitors on metabolism. Neuropharmacology 10: 547–556PubMedCrossRefGoogle Scholar
  67. Spencer C, Faulds D, Fitton A (1993) Ibopamine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in congestive heart failure. Drugs & Aging 3(6): 556–584CrossRefGoogle Scholar
  68. Steiner A, Walle UK, Walle T (1992) Induction of propranolol metabolism in the Hep G2 human hepatoma cell line. J Pharm Pharmacol 44: 611–614PubMedCrossRefGoogle Scholar
  69. Strolin Benedetti M, Dostert P (1992) Monoamine oxidase: from physiology and pathophysiology to the design and clinical application of reversible inhibitors. Drug Res 23: 65–125Google Scholar
  70. Strolin Benedetti M, Dostert P (1994) Contribution of amine oxidases to the metabolism of xenobiotics. Drug Metab Rev 26: 507–535PubMedCrossRefGoogle Scholar
  71. Strolin Benedetti M, Rovei V, Thiola A, Donath A (1984) In: Tipton KF, Dostert P, Strolin Benedetti M (eds) Monoamine oxidase and disease: prospects for therapy with reversible inhibitors. Academic Press, London, p 203Google Scholar
  72. Strolin Benedetti M, Dostert P, Tipton KF (1988) Contributions of monoamine oxidase to the metabolism of xenobiotics. Progr Drug Metab 11: 149–174Google Scholar
  73. Strolin Benedetti M, Allievi C, Cocchiara G, Pevarello P, Dostert P (1992) Involvement of FAD-dependent polyamine oxidase in the metabolism of milacemide in the rat. Xenobiotica 22(2): 191–197CrossRefGoogle Scholar
  74. Strolin Benedetti M, Marrari P, Colombo M, Castelli MG, Arand M, Oesch F, Dostert P (1994) The anticonvulsant FCE 26743 is a selective and short-acting MAO-B inhibitor devoid of inducing properties towards cytochrome P450-dependent testosterone hydroxylation in mice and rats. J Pharm Pharmacol 46: 814–819CrossRefGoogle Scholar
  75. Strolin Benedetti M, Sanson G, Bona L, Gallina M, Persiani S, Tipton KF (1996) 6th Amine Rappaport Symposium and 7th International Amine Oxidase Workshop, Haifa, June 10–13, 1996. Book of Abstracts, p 14Google Scholar
  76. Subramanyam B, Rollema H, Woolf T, Castagnoli N Jr (1990) Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem Biophys Res Commun 166: 238–244PubMedCrossRefGoogle Scholar
  77. Subramanyam B, Pond SM, Eyles DW, Whiteford HA, Fouda HG, Castagnoli N Jr (1991) Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol. Biochem Biophys Res Commun 181: 573–578PubMedCrossRefGoogle Scholar
  78. Suzuki O, Matsumoto T, Katsumata Y (1984) Determination of polyamine oxidase activities in human tissues. Experientia 40: 838–839PubMedCrossRefGoogle Scholar
  79. Tateishi T, Fujimura A, Shiga T, Ohashi K, Ebihara A (1995) Influence of aging on the oxidative and conjugative metabolism of propranolol. Int J Clin Pharm Res XV(3): 95–101Google Scholar
  80. Teramoto T, Takahashi N, Yamada F, Fukazawa I, Oguchi K, Yasuhara H (1987) Inhibitory effects of antiarrhythmic drugs on rat heart and liver monoamine oxidase. Asia Pac J Pharmacol 2: 275–279Google Scholar
  81. Tetrud JW, Langston JW (1989) MPTP-induced parkinsonism as a model for Parkinson’s disease. Acta Neurol Scand [Suppl] 126: 35–40CrossRefGoogle Scholar
  82. Thomas PE, Bandiera S, Maines SL, Ryan DE, Levin W (1987) Regulation of cytochrome P-450j, a high-affinity N-nitrosodimethylamine demethylase, in rat hepatic microsomes. Biochemistry 26: 2280–2289PubMedCrossRefGoogle Scholar
  83. Tipton KF, Singer TP (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 61: 1191–1206PubMedCrossRefGoogle Scholar
  84. Worth DP, Harvey JN, Brown J, Lee MR (1985) y-L-Glutamyl-L-dopa is a dopamine prodrug, relatively specific for the kidney in normal subjects. Clin Sci 69: 207–214PubMedGoogle Scholar
  85. Yoshikawa M, Endo H, Komatsu K, Fujihara M, Takaiti O, Kagoshima T, Umehara M, Ishikawa H (1990) Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis (ethoxycarbonyl) dopamine (TA-870) in humans. Drug Metab Dispos 18(2): 212–217PubMedGoogle Scholar
  86. Yoshimoto K, Echizen H, Chiba K, Tani M, Ishizaki T (1995) Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers-N-desisopropylation is mediated mainly by CYP1A2. Br J Clin Pharmacol 39: 421–431PubMedCrossRefGoogle Scholar
  87. Yu PH, Davis BA (1991a) 2-propyl-1-aminopentane, its deamination by monoamine oxidase and semicarbazide-sensitive amine oxidase, conversion to valproic acid and behavioral effects. Neuropharmacology 30: 507–515PubMedCrossRefGoogle Scholar
  88. Yu PH, Davis BA (1991b) Simultaneous delivery of valproic acid and glycine to the brain. Deamination of 2-propylpentylglycinamide by monoamine oxidase B. Mol Chem Neuropathol 15: 37–49PubMedCrossRefGoogle Scholar
  89. Yu PH, Tipton KF (1989) Deuterium isotope effect of phenelzine on the inhibition of rat liver mitochondrial monoamine oxidase activity. Biochem Pharmacol 38(23): 4245–4251PubMedCrossRefGoogle Scholar
  90. Ziegler DM (1988) Flavin-containing monooxygenases: catalytic mechanism and substrate specificities. Drug Metab Rev 19: 1–32PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1998

Authors and Affiliations

  • M. Strolin Benedetti
    • 1
    • 3
  • K. F. Tipton
    • 2
  1. 1.Department of Preclinical Development and Human PharmacologyZambon GroupBressoItaly
  2. 2.Department of BiochemistryTrinity CollegeDublinIreland
  3. 3.Preclinical Development and Human PharmacologyZambon GroupBressoItaly

Personalised recommendations